In this study, several influenza NS1 mutants were examined for their growth ability in interferon (IFN)-deficient Vero cells treated with human interferon alpha (IFN-a). Mutants with an intact RNA binding domain showed similar growth properties as the wild-type virus, whereas viruses carrying an impaired RNA binding domain were dramatically attenuated. Relying on the ability of the first half of the NS1 protein to antagonize the IFN action, we established a rescue system for the NS gene based on the transfection of one plasmid expressing recombinant NS vRNA and subsequent coinfection with an IFN sensitive helper virus followed by adding of human IFN-a as a selection drug. Using this method, a recombinant influenza A virus expressing green fluorescence protein (GFP) from the NS1 reading frame was rescued. To ensure the posttranslational cleavage of GFP from the N-terminal 125 amino acids (aa) of NS1 protein, a peptide sequence comprising a caspase recognition site (CRS) was inserted upstream the GFP protein. Although a rather long sequence of 275 aa was inserted into the NS1 reading frame, the rescued recombinant vector appeared to be genetically stable while passaging in Vero cells and was able to replicate in PKR knockout mice.
Introduction
Influenza A viruses belong to the family Orthomyxoviridae and contain a segmented RNA genome consisting of eight genomic fragments of negative polarity. Reverse genetic methods have provided an excellent tool for the studies of influenza virus genetics and for the development of new generations of influenza vaccines and vectors (Enami et al., 1990; Fodor et al., 1999; Luytjes et al., 1989; . One of the extensively used targets for genetic manipulation of influenza A viruses is the nonstructural protein 1 (NS1). It consists of approximately 230 amino acids (aa), is early and abundantly synthesized in infection, accumulated in the nucleus and later in the cytoplasm of the infected cells (Krug and Soeiro, 1975; Lamb and Krug, 2001 ). The NS1 protein has been suggested to perform several important accessory functions for the effective replication of the virus in its host. First, by the activity of its carboxy-terminal domain, the NS1 protein is able to inhibit the host mRNA's processing mechanisms (Krug et al., 2003) . Second, it facilitates the preferential translation of viral mRNA by direct interaction with the cellular translation initiation factor eIF4GI (Aragon et al., 2000) . Third, by binding to dsRNA and interaction with putative cellular kinase(s), the NS1 protein is able to prevent the activation of interferon (IFN)-inducible dsRNA-activated kinase (PKR) (Bergmann et al., 2000; Hatada et al., 1999; Tan and Katze, 1998) , 2V,5V-oligoadenylate synthetase system, and cytokine transcription factors such as NF-nB or IRF 3 and c-Jun/ATF2 (Smith et al., 2001; Talon et al., 2000; Wang et al., 2000) . As result, the NS1 protein inhibits the expression of INF-a and INF-h genes, delays the development of apoptosis in the infected cells, and prevents the formation of the antiviral state in neighboring cells.
The function of the NS1 protein as an a/h IFN antagonist was proven by the construction of several NS mutants bearing C-terminal deletions that showed impaired growth properties in IFN-competent cells such as MDCK, embryonated chicken eggs, or mouse lungs, but had no attenuation effect in IFN-deficient hosts such as Vero cells (Egorov et al., 1998) or PKR knockout mice (Bergmann et al., 2000) . It was found that an influenza NS mutant coding for just the first N-terminal 125 amino acids was only slightly attenuated in IFN-competent systems, while mutants carrying shorter versions, respectively, less than 80 aa of the NS1 protein, were dramatically attenuated in MDCK cells and mice (Egorov et al., 1998; Garcia-Sastre, 2002) .
As mentioned before, Vero cells are defective in IFN type I production due to a spontaneous gene deletion (Desmyter et al., 1968; Mosca and Pitha, 1986) . However, these cells are competent responders to the treatment with exogenous human interferon (IFN) (Lambropoulos and Koliais, 1989; Schlender et al., 2000) . In this study, we tested the ability of several influenza A NS deletion mutants to circumvent the antiviral state of Vero cells treated with human interferon alpha (IFN-a). We found that NS mutants encoding for the N-terminal 125 aa of the NS1 protein, but not mutants like delNS1, completely lacking the NS1 ORF, were fully resistant to the interferon action and were replicating as efficient as the wild-type virus in human IFN-a-treated cells. This encouraged us to establish a reverse genetic system in Vero cells in which influenza NS transfectants could be obtained with the help of human IFN-a used as a selection drug against an IFN-sensitive helper virus. The high efficiency of this system allowed us to rescue a genetically stable influenza virus expressing green fluorescence protein (GFP) from the NS1 reading frame.
Results

Growth of influenza NS mutants in Vero cells treated with human IFN-a
To determine the IFN sensitivity of NS mutants, Vero cells were infected with the wild-type PR8 virus or three different NS mutants containing either only 125 N-terminal aa (NS1 -125), lacking NS1 ORF (delNS1), or harboring a 40 aa deletion (NS1-del40-80) in the N-terminal part of the molecule (Fig. 1) . The infected cells were incubated in the presence or absence of 30 U/ml human IFN-a and the viral titers were compared 36 h postinfection. We found that mutants delNS1 and NS1-del40-80 containing an impaired RNA binding -dimerization domain showed dramatic attenuation in growth under the pressure of IFN-a, whereas the wild-type virus, as well as the NS1 -125 mutant, containing an intact RNA binding domain showed almost similar titers when incubated in the presence or absence of IFN-a (Fig.  1) . Thus, the first N-terminal 125 aa of the NS1 protein could serve as a resistance factor responsible for the antagonizing of IFN action.
Rescuing of GFP-expressing influenza NS vector
Vero cells were transfected with plasmids expressing the components of the influenza RNP complex and the plasmid pPol-NS-Casp-GFP-HDV encoding chimeric vRNA in which GFP was cloned into the NS1 reading frame ( Fig. 1 ) after aa 125. In addition, an artificial CRS (DIDGGETDG) was introduced between those two proteins to provide posttranslational separation of the molecules.
Transfected cells were infected with an IFN-sensitive helper virus (delNS1), and the virus yield was harvested 48 h postinfection. This yield contained at least 10 2 PFU/ml progeny of the ''fluorescent virus'' and 10 5 PFU/ml of the helper virus, determined by limiting dilution assay in Vero cells without IFN-a treatment. Two passages in Vero cells in the presence of IFN-a were performed to enrich the population of the transfectant virus, and a pure GFP expressing plaque was isolated. Further two rounds of plaque purification in Vero cells, in which plaques were routinely examined for GFP expression, allowed us to isolate a pure clone of GFP-expressing virus designated as A/PR8/NS1-125GFP (NS1-GFP). This virus, when applied at MOI = 1, was able to induce expression of GFP as early as 6 h postinfection in Vero and MDCK cells with full manifestation 24 h postinfection (Fig. 2) . By Western blot analysis, we confirmed that insertion of the CRS permitted the posttranslational cleavage of GFP from the N-terminal part of the NS1 protein Fig. 1 . Schematic structure of the NS1 proteins and growth on Vero cells in the presence of human IFN-a. Titers of the influenza PR8 virus and NS mutants grown in the presence or absence of 30 U/ml human IFN-a in Vero cells were determined 36 h postinfection using a plaquing assay on Vero cells. For the recombinant NS1-GFP protein, an artificial caspase recognition site containing the motif DIDGGETDG was inserted after amino acid 125 of NS1 followed by the GFP sequence. Arrows are marking the position of the putative caspase cleavage site. (Fig. 3) . Adding of general caspase inhibitor Z-VAD-FMK (R&D Systems) to the medium anticipated the cleavage, confirming that cleavage occurred due to host cells caspase activity. Moreover, the omitting of cleavage by caspase inhibitors provoked the generation of deletion mutants manifesting in several additional bands seen in the Western blot (specially lane 2, Fig. 3 ).
Growth capacity of NS-GFP expression vector
The recombinant NS1-GFP virus was capable of replicating in Vero cells up to the titers of 10 6 -10 7 PFU/ml and was not significantly attenuated in MDCK (Fig. 3) or in Vero cells treated with 30 U/ml IFN-a (Fig. 1) . Nevertheless, the genetic stability of the virus was not equal in IFN- deficient or -competent cell substrates. In contrast to Vero, passages in MDCK were causing an appearance of NS-GFP deletion mutants in high frequency accompanied by the loss of GFP expression after several passages. Sequence data of these mutants confirmed that parts of the GFP encoding sequence were removed due to spontaneous gene deletion. The originated deletions were very heterogeneous, ranging from several nucleotides up to the removal of approximately 80% of the C terminal part of the GFP protein. However, deletion occurred solely in the GFP and never in the NS1 encoding sequence.
Replication in mice
Virus NS1-GFP revealed a full attenuation in the wildtype mice (C57BL/6) as compared to the NS125 mutant, which reached a titer of 5 Â 10 4 PFU/g in the lung tissues 2 days postinfection (Fig. 4) . However, the infection of PKR knockout (PKR À/À ) mice, previously shown to support the replication of the delNS1 virus, resulted in the replication of the GFP expressing vector in lung tissues to 4 Â 10 4 PFU/g, detected 2 days postinfection. Furthermore, even after 2 days of replication in mouse lungs, the virus was still expressing GFP when titrated in Vero cells.
Discussion
The influenza virus is considered a potential vaccine vector that could deliver various antigens into nasal tissues inducing systemic and mucosal T-and B-cell immune response (Ferko et al., 2001; Garcia-Sastre and Palese, 1995) . One of the advantages of using the influenza virus as viral vectors, in contrast to other systems such as adenoviral vectors or retroviruses, is that it does not contain a DNA intermediate and therefore is not able to integrate into the host's chromosomes. In addition, live influenza virus vaccines have been developed and licensed for humans and can be theoretically used for the expression of additional antigens. The influenza NS1 protein has several advantages as a target for engineering because it has a nonstructural nature and therefore does not presumably interfere with the structure of the virions, but is synthesized in large quantities in infected cells. Several groups have succeeded in introducing foreign protein sequences such as CAT or HIV Nef into the NS1 reading frame of influenza A virus. Furthermore, it has been shown that influenza viruses expressing foreign epitopes from the NS1 reading frame could elicit both humoral and cellular immune responses (Ferko et al., 2001; Takasuka et al., 2002) . However, it still remains to be elucidated what could be the maximal length of inserted foreign sequences that influenza A NS1 protein can tolerate and where would the optimal position be for introducing them. This requires better understanding of the structure -functional organization of the NS1 molecule.
One of the well-determined functions of the NS1 protein is its ability to antagonize an a/h IFN-induced antiviral response. The mechanisms by which the NS1 protein exerts its function to evade the host antiviral response are not yet fully understood. However, it is clear that in primary infected cells, one of the main strategies of the influenza virus is to inhibit IFNa/h signaling to the neighboring cells, which can induce their antiviral state by stimulation of transcription INF-stimulated response element (ISRE) promoter containing genes (Stark et al., 1998) . Among hundreds of genes transcriptionally stimulated by interferons, several are involved in the inhibition of viral replication: the PKR, the 2V, 5V-oligoadenylate synthetases, and the Mx protein (Garcia-Sastre, 2002). Many viruses have evolved different mechanisms to counteract with interferon response. In this report, we demonstrated that influenza viruses carrying the wt NS gene or mutants encoding 125 N-terminal aa of NS1 protein can efficiently grow in Vero cells treated with human IFN-a, whereas mutants with an affected RNA binding domain are fully attenuated. In other words, we have demonstrated that the influenza virus is able to circumvent the antiviral state of the interferon-treated cells most likely by the activity of the NS1 protein RNA binding domain.
Using the 125 aa N-terminal half of the NS1 protein as a drug resistance factor, we established a reverse genetic system for the influenza NS gene that combines transfection of Vero cells with a plasmid expressing recombinant NS vRNA and infection with IFN-sensitive delNS1 helper virus under IFN-a pressure. The delNS1 virus, after playing the part of its helper function, was easily eliminated from the viral population by treatment of Vero cells with human IFNa. This system appeared to be a powerful tool for the obtaining of various influenza NS mutants (data not shown). As a challenge for the efficacy of this method, we tried to obtain an influenza virus expressing GFP from the NS1 ORF. It is important to mention that previous attempts to rescue NS transfectants with inserts of more than 275 aa (e.g., GFP) using plasmid only transfection system were not fruitful.
For the rescuing of the GFP expressing vector, we had to enhance the efficiency of our rescue system by co-transfection of additional four plasmids expressing the proteins of the viral polymerase complex (RNP), as described in Pleschka et al. (1996) . In addition, a new cleavage site encoding a caspase recognition sequence was introduced to provide posttranslational separation of the parts of the recombinant NS1 molecule. The rescued NS1-GFP virus was replicating to high titers and was genetically stable while passaging in Vero cells, generating 100% fluorescent plaques. At the same time, although the virus was growing and expressing GFP in IFN competent cells, it was losing its fluorescing activity due to the appearance of various deletions within the GFP sequence. Therefore, it can be concluded that although the virus had an intact N-terminal part of the NS1 protein that was efficiently released from the GFP molecule by caspase cleavage, the IFN antagonizing function of NS1-GFP virus was still partially compromised. Although the NS1-GFP virus was growing in IFN-competent cells, it was not able to replicate in wild-type C57/bl mice, behaving quite similar as the delNS1 virus, which completely lacks the NS1 ORF. In contrast, PKR knockout mice were supporting the replication of NS1-GFP virus in the lungs having a titer of more than 10 4 PFU/g of lung tissues, as it was shown for delNS1 (Bergmann et al., 2000) . Moreover, even after 2 days of replication in mouse lungs, the virus did not lose its capacity to express GFP.
The effect that influenza NS mutants carrying carboxyterminal deletions are replicating to high titers in tissue culture but are significantly attenuated in wt mice was previously described and studied (Wang et al., 2002) . In fact, several vectors that were constructed in our laboratory by inserting foreign sequences into aa position 125 of NS1 were replication-deficient in mice despite their capacity to grow in IFN-a-treated Vero cells. Several reasons should be considered as an explanation of this attenuation effect in vivo. First, the lack of the NS1 effector domain could already cause some extent of attenuation and its function could be more important in animals than in tissue culture. Second, recently, it has been demonstrated that attenuated influenza NS1 mutants carrying just 73 or 126 aa of the N-terminal part of NS1 could be converted to a more virulent phenotype by elongation of the NS1 with the sequences promoting dimerization (Wang et al., 2002) . In our case, the GFP insert could have some negative influence on the formation of the NS1 dimers, making NS1 function to be less efficient and therefore promoting the activation of PKR. Finally, it has to be elucidated what kind of attenuation effect the inserted CRS may have by interacting with various caspases in the infected cells. Our preliminary results have indicated that the created CRS resulted in the delay of nucleoaccumulation of the NS1 protein in infected cells.
In conclusion, we have demonstrated that the influenza virus can be engineered in such a way that foreign sequences that are even longer than the NS1 protein itself can be expressed from the NS1 reading frame and that such viruses could be successfully maintained and propagated to high titers in Vero cells. In addition, the constructed GFP expressing viral vector could be used as a tool for the tracking of influenza virus infection in knockout animals and for the fast screening of antiviral drugs against influenza.
Materials and methods
Viruses and cells
Vero and MDCK cell lines originate from the American Type Culture Collection (ATCC). Vero cells were adapted to and further cultivated in DMEM -Ham's F12 (Biochrom F4815) with 4 mM L-glutamine and protein-free supplement (proprietary formulation, Polymun Scientific GmbH, Austria). MDCK cells were cultivated in DMEM -Ham's F12 medium containing 2% heat-inactivated fetal calf serum (FCS, HyClone SH30071) and 4 mM L-glutamine. Influenza virus A/PR/8/34 (H1N1) (PR8) and NS mutants A/PR8/ delNS1 (delNS1), A/PR8/NS1-125 (NS1-125), and A/PR8/ NS1-del40-80 (NS1-del40-80) (Fig. 1) were obtained in Vero cells by using the transfection protocol as described in Egorov et al. (1998) . All viruses were grown and titrated in Vero cells at 37 jC.
Construction of plasmids
Viral RNA from influenza PR8 was extracted with Ultraspec RNA purification reagent (Biotecx Laboratories), reverse transcribed using M-MuLV reverse transcriptase (MBI), and served as a template for subsequent amplification of the NS gene by PCR. The NS sequence was blunt end cloned between the PolI promoter and the Hepatitis delta virus (HDV) genomic ribozyme and designated as pPolI-NS-HDV (Fodor et al., 1999; Pleschka et al., 1996; Poomputsa et al., 2003) . Oligonucleotides coding for the CRS (5V-ATTGATG-GAGGTGAAACTGATGGG-3V and 5V-CCCATCAGTTT-CACCTCCATCAAT-3V) were synthesized (Invitrogen), annealed, and blunt end ligated into plasmid pPolI-NS-HDV after nucleotide position 400 of NS and the resulting plasmid was named pPol-NS125Casp-HDV. Insertion of the GFP encoding sequence (Quantum's SuperGlok GFP, extracted from Vector pQBI25-fc1, Qbiogene) into plasmid pPol-NS125Casp-HDV downstream the CRS resulted in the plasmid pPol-NS-Casp-GFP-HDV. The expression plasmids for PB1, PB2, PA, and NP influenza proteins were obtained by cloning of the corresponding PR8 genes into the Vector pTriEx-1 (Novagene) under the chicken actin promoter and designated pTriEx-PB1, pTriEx-PB2, pTriEx-PA, and pTriEx-NP, respectively.
Generation of transfectant viruses
Ninety percent confluent Vero cells were transfected with 1 Ag of each plasmid pPol-NS-Casp-GFP-HDV, pTriEx-NP, pTriEx-PA, pTriEx-PB1, and pTriEx-PB2 using the Nucleofection technique (Amaxa), according to the manufacturer's instruction manual. Twenty-four hours later, cells were examined for GFP expression and infected with delNS1 helper virus (MOI = 0.1). Eight hours postinfection, 3 U of human IFN-a (NIBSC 1st International Standard 1999, human leukocyte derived, suspended in RPMI media (Biochrom F1512) containing 10% heatinactivated fetal calf serum and 4 mM L-glutamine) per ml culture medium was added and cells were incubated 48 h at 37 jC. The supernatant was passaged twice in Vero cells in the presence of IFN-a at a concentration of 3 U/ ml and plaqued in Vero cells. Plaques containing the correct NS1-GFP gene were identified by RT-PCR. Following two rounds of plaque purification, in which plaques were routinely examined for GFP expression, a pure virus could be isolated. This virus was designated as A/PR8/ NS1-125GFP (NS1-GFP), analyzed by RT-PCR, and the correct sequence was confirmed by nucleotide sequence analysis.
Viral replication in mouse lungs
Four-to 6-week-old C57BL/6 mice or PKR knockout (PKR À/À ) mice, which were derived from C57BL/6 mice by the targeted deletion of PKR (Yang et al., 1995) , were infected intranasally (in) with 5 Â 10 4 PFU/animal of the virus under ether anesthesia. At day two, mice were sacrificed and lungs aseptically removed. A 10% tissue extract in PBS was prepared by grinding the tissue sample with a rotor homogenizer. The suspension was centrifuged at 2000 Â g for 5 min and the viral yield of the supernatants was determined by limiting dilution assay in Vero cells.
Polyacrylamide gel electrophoresis and Western blot analysis
SDS-PAGE of virus preparations was carried out using Tris-Glycine 16% gels (Anamed). Western blotting was performed by electrophoretic transfer of the proteins from the gel to a polyvinyl difluoride membrane (Millipore) for 2 h at 400 mA. After overnight blocking in TPBS (PBS with 0.1% Tween 20) containing 3% of skim milk, the membrane was incubated for 1 h with specific mouse anti-NS1-GST or rabbit anti-GFP antisera (Clontech) and diluted 1:5000 in TPBS buffer containing 1% of skim milk. After washing with TPBS, the membrane was either incubated for 1 h with anti-mouse alkaline phosphatase or anti-rabbit peroxidaselabeled conjugate (Sigma) diluted 1:40 000 in TPBS containing 1% of skim milk. The blots were developed in staining buffer (100 mM Tris -HCl, 100 mM NaCl, 5 mM MgCl 2 , pH 9.5) with nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate or by ECL plus Western Blotting Detection system (Amersham) for chemoluminescence, respectively.
